Several analysts have recently updated their ratings and price targets for GlaxoSmithKline plc (LON: GSK):

  • 9/20/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 1,900 ($24.80) price target on the stock.
  • 9/20/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Goldman Sachs Group Inc.. They now have a GBX 1,800 ($23.50) price target on the stock.
  • 9/16/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Beaufort Securities.
  • 9/16/2016 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 9/14/2016 – GlaxoSmithKline plc was downgraded by analysts at BNP Paribas to an “underperform” rating. They now have a GBX 1,520 ($19.84) price target on the stock.
  • 9/14/2016 – GlaxoSmithKline plc had its “sell” rating reaffirmed by analysts at Societe Generale. They now have a GBX 1,320 ($17.23) price target on the stock.
  • 9/13/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 1,900 ($24.80) price target on the stock.
  • 9/13/2016 – GlaxoSmithKline plc had its price target lowered by analysts at Jefferies Group from GBX 2,000 ($26.11) to GBX 1,900 ($24.80). They now have a “buy” rating on the stock.
  • 9/12/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at HSBC. They now have a GBX 1,970 ($25.71) price target on the stock.
  • 9/8/2016 – GlaxoSmithKline plc was downgraded by analysts at Societe Generale to a “sell” rating. They now have a GBX 1,320 ($17.23) price target on the stock, up previously from GBX 1,300 ($16.97).
  • 9/8/2016 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Deutsche Bank AG.
  • 9/6/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Beaufort Securities.
  • 9/5/2016 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 9/2/2016 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 1,800 ($23.50) price target on the stock.
  • 8/23/2016 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a GBX 1,900 ($24.80) price target on the stock.
  • 8/17/2016 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 8/12/2016 – GlaxoSmithKline plc had its price target raised by analysts at JPMorgan Chase & Co. from GBX 1,800 ($23.50) to GBX 1,900 ($24.80). They now have a “neutral” rating on the stock.
  • 8/10/2016 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 8/9/2016 – GlaxoSmithKline plc was given a new GBX 1,885 ($24.61) price target on by analysts at Berenberg Bank. They now have a “neutral” rating on the stock.
  • 8/4/2016 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at BNP Paribas. They now have a GBX 1,560 ($20.36) price target on the stock.
  • 8/4/2016 – GlaxoSmithKline plc was given a new GBX 1,800 ($23.50) price target on by analysts at Independent Research GmbH. They now have a “neutral” rating on the stock.
  • 8/4/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a GBX 2,000 ($26.11) price target on the stock.
  • 8/2/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Beaufort Securities.
  • 7/29/2016 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at BNP Paribas.
  • 7/29/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a GBX 2,000 ($26.11) price target on the stock.
  • 7/28/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Bryan, Garnier & Co.
  • 7/28/2016 – GlaxoSmithKline plc was given a new GBX 1,755 ($22.91) price target on by analysts at Sanford C. Bernstein. They now have a “neutral” rating on the stock.
  • 7/28/2016 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 1,700 ($22.19) price target on the stock.
  • 7/28/2016 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 7/27/2016 – GlaxoSmithKline plc was given a new GBX 1,650 ($21.54) price target on by analysts at S&P Global Inc.. They now have a “neutral” rating on the stock.
  • 7/27/2016 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 7/27/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Citigroup Inc..

GlaxoSmithKline plc (LON:GSK) opened at 1640.50 on Wednesday. GlaxoSmithKline plc has a 52-week low of GBX 1,227.50 and a 52-week high of GBX 1,716.50. The company’s 50-day moving average price is GBX 1,655.81 and its 200 day moving average price is GBX 1,530.22. The stock’s market capitalization is GBX 79.74 billion.

The firm also recently announced a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th will be paid a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, August 11th. This represents a yield of 1.12%.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/research-analysts-weekly-ratings-updates-for-glaxosmithkline-plc-gsk-2.html

In other news, insider Cartwright,Stacey purchased 461 shares of the company’s stock in a transaction dated Friday, July 1st. The shares were purchased at an average cost of GBX 1,559 ($20.35) per share, for a total transaction of £7,186.99 ($9,381.27). Also, insider Witty,Sir Andrew P sold 10,000 shares of the firm’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($22.10), for a total value of £169,300 ($220,989.43).

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.